Hit Enter to search or Esc to close
0
Latanoprostene bunod

Latanoprostene bunod

CAS: 860005-21-6
MF: C27H41NO8
Molecular weight :507.62
API403
Quantity
Send Inquiry
add to cart

Product Name
Latanoprostene bunod
Appearance
Colorless to light yellow liquid
Specification
 95%
Test Method
HPLC
Storage
Keep in a cool, dry, dark location in a tightly sealed container or cylinder.
Shelf Time
24 months

Latanoprostene Bunods a novel prostaglandin analog combined with a nitric oxide (NO) donor,

designed to address elevated intraocular pressure (IOP) in patients with open-angle glaucoma (OAG) or ocular hypertension (OHT). 
Approved by the FDA in 2017 under the brand name VYZULTA, it is developed and marketed by Bausch + Lomb, a global leader in ophthalmic care.

This innovative molecule uniquely integrates two mechanisms of action, offering enhanced efficacy compared to traditional glaucoma therapies.

Latanoprostene bunod Once-Daily Convenience
Administered as a once-daily topical ophthalmic solution, Latanoprostene Bunod simplifies treatment regimens, improving patient adherence compared to multi-dose therapies.
Favorable Safety Profile
Common side effects are mild and transient, including conjunctival hyperemia and eye irritation. Unlike beta-blockers, it avoids systemic effects such as bradycardia or respiratory complications.

Latanoprostene bunod is indicated for:

  • Open-Angle Glaucoma (OAG): Reduces IOP in patients with progressive optic nerve damage115.

  • Ocular Hypertension (OHT): Manages elevated IOP in patients at risk of developing glaucoma1016.

  • Adjunctive Therapy: May be combined with other IOP-lowering agents in refractory cases, though fixed-dose combinations are still under exploration